Clinical trials
Obstructive Hypertrophic Cardiomyopathy clinical trials
Below are recruiting obstructive hypertrophic cardiomyopathy clinical trials, each written for real people, not researchers. We’re tracking 35 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06580717RecruitingPhase 4
Testing empagliflozin for heart stiffness in hypertrophic cardiomyopathy
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
SeoulAges 19–80 - NCT07120776Recruiting
PET scan study for chest pain in hypertrophic cardiomyopathy
This trial uses a special PET scan to see if the drug Mavacamten (Camzyos) helps improve blood flow to the heart muscle in people with hypertrophic obstructive cardiomyopathy (HOCM) who have chest pain or shortness of breath. If you already take Mavacamten as part of your usual care, the study will compare your PET scan results before and after treatment.
ManchesterAges 18 years+ - NCT07541833Recruiting
Mavacamten Treatment Patterns in Obstructive Heart Thickening
This study tracks how mavacamten (a heart medication) works in Japanese patients with obstructive hypertrophic cardiomyopathy—a condition where the heart muscle becomes abnormally thick and blocks blood flow. The trial aims to understand how well the treatment works and how doctors use it in real-world care.
Minato-ku, TokyoAges 18 years+ - NCT05610215Recruiting
Hybrid or catheter ablation for atrial fibrillation in hypertrophic heart
This trial compares two procedures to treat atrial fibrillation (an irregular heartbeat) in people who also have hypertrophic cardiomyopathy (thickened heart muscle). It looks at whether the hybrid approach or a catheter-based approach works better for controlling symptoms and heart rhythm.
BeijingAges 18 years+ - NCT04080492Recruiting
Quality of life study for heart disease patients
This study asks people with certain heart conditions to complete follow-up questionnaires to better understand how their quality of life changes over time. It may help improve how care plans are made and supported for patients and their families.
Cleveland, OhioAges 18–70 - NCT06023186Recruiting
Effect of mavacamten on heart blood flow in HCM
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
Charlottesville, VirginiaAges 18–85 - NCT06551129Recruiting
Camzyos treatment in real life: patient experiences
This study tracks how people with obstructive hypertrophic cardiomyopathy feel and function while taking Camzyos (mavacamten). It aims to understand the real-world effects of the medication beyond clinical trials.
Boston, MassachusettsAges 18 years+ - NCT07344480Recruiting
Study on heart disease in children with RASopathy
This study looks at medical records of children with a genetic condition called RASopathy who developed thickened heart muscle and needed hospital care for heart failure in their first six months of life. The goal is to understand how the heart condition progresses over time.
MünchenAges Any age - NCT05836259RecruitingPhase 1/Phase 2
TN-201 for heart symptoms from MYBPC3 heart disease
This early trial tests TN-201 to see how safe it is and how well it works to reduce symptoms in adults with MYBPC3-related hypertrophic cardiomyopathy. It’s designed to learn safe dosing, and you may be eligible if you have specific genetic heart changes and ongoing symptoms.
La Jolla, CaliforniaAges 18–75 - NCT07054073Recruiting
HCMR Re-Imaging: MRI follow-up for HCM patients
This study uses MRI scans to re-examine people with hypertrophic cardiomyopathy (a thickening of the heart muscle) who were part of the original HCMR study. It compares different types of HCM to learn more over time.
Evanston, IllinoisAges 18–65 - NCT01793168Recruiting
Rare disease registry and history study
This study keeps a registry (a structured list) of people with rare diseases and may also track how the condition changes over time. It can help researchers better understand rare illnesses and find gaps in care, which may improve future treatments.
Sioux Falls, South DakotaAges Any age
Hear when a new Obstructive Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for obstructive hypertrophic cardiomyopathy?
- Yes. Clin2 currently lists 35 recruiting obstructive hypertrophic cardiomyopathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a obstructive hypertrophic cardiomyopathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a obstructive hypertrophic cardiomyopathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.